• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Zimmer Biomet Holdings (ZBH) Could Be 13% Below Fair Value After Leadership Reshuffle

    Simply Wall St·09/13/2026 08:20:14
    語音播報

    Zimmer Biomet Holdings (ZBH) has kicked off a broad leadership reshuffle, promoting three senior executives and redefining responsibilities across Americas operations, reconstruction, robotics, technology and data, while a long-serving group president prepares to exit.

    Recent trading tells a mixed story for Zimmer Biomet Holdings, with the share price at US$93.49, a 1-day share price return of 1.14%, a 30-day share price return that fell 7.11%, a 1-year total shareholder return that declined 8.35%, and a 5-year total shareholder return that is down 31.41%. This suggests longer term momentum has faded even as management reshapes the business with this leadership overhaul.

    Spot 39 healthcare AI stocks that, like Zimmer Biomet Holdings, are leaning into robotics, data and AI to reshape how procedures are planned, executed and monitored.

    Zimmer Biomet Holdings is reshaping its leadership while the share price has already retreated. Do you lean into the overhaul now, or wait for a cheaper entry before the valuation work stacks up for you?

    Most Popular Narrative: 13.1% Undervalued

    The most followed valuation narrative for Zimmer Biomet Holdings pegs fair value at $107.57, above the last close of $93.49. This puts the recent leadership reshuffle against a backdrop of perceived undervaluation.

    The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

    Read the complete narrative.

    It is worth considering what kind of revenue run-rate, margin lift, and future earnings power are implied by the $107.57 figure. The narrative emphasizes procedure volumes, higher value robotic systems, and a richer profit profile. The key issue is how much execution room Zimmer Biomet Holdings has before that valuation view is challenged or begins to look conservative.

    Result: Fair Value of $107.57 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    Still, the Zimmer Biomet Holdings story can break if pricing pressure keeps selling prices flat for longer than analysts expect, or if recent acquisitions struggle to lift margins and cash generation.

    Find out about the key risks to this Zimmer Biomet Holdings narrative.

    Next Steps

    If the Zimmer Biomet Holdings story feels finely balanced between promise and concern, consider acting while sentiment is split and pressure test the thesis yourself with the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Zimmer Biomet Holdings?

    Do not stop at Zimmer Biomet Holdings when there are other opportunities to test, compare and pressure check your investment thinking across different styles and risk levels.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.